TABLE 3

In vitro activity of imipenem-relebactam against the most common MDR phenotypes of non-Proteeae Enterobacteriaceae

Phenotypean (% of all MDR isolates)Imipenem-relebactam
MIC90 (μg/ml)% susceptible
All non-Proteeae Enterobacteriaceae3,1430.2599.1
    All MDR452b0.598.2
        ATM, CAZ, FEP, CIP137 (30.3)0.25100
        ATM, CAZ, P/T69 (15.3)0.25100
        ATM, CAZ, FEP, CIP, P/T57 (12.6)0.25100
        ATM, CAZ, FEP, P/T31 (6.9)0.25100
        ATM, FEP, CIP28 (6.2)0.25100
        ATM, CAZ, FEP21 (4.6)0.5100
        ATM, CAZ, FEP, CIP, IMI, P/T18 (4.0)488.9
        ATM, CAZ, FEP, IMI, P/T10 (2.2)0.25100
  • a Sentinel agents used for the definition of MDR included amikacin, aztreonam (ATM), cefepime (FEP), ceftazidime (CAZ), ciprofloxacin (CIP), colistin, imipenem (IMI), and piperacillin-tazobactam (P/T). The MDR phenotypes listed accounted for 82.1% (371/452) of all MDR phenotypes identified; amikacin or colistin resistance was not observed among the most common MDR phenotypes identified. Agents shown in the table tested as nonsusceptible; the other sentinel agents tested as susceptible. Agents tested but not included in the list of sentinel agents may have tested as susceptible or nonsusceptible.

  • b MDR isolates accounted for 14.4% (452/3,143) of all isolates of non-Proteeae Enterobacteriaceae.